Evidence map›Paper›PMID 40232159›Full record

ArticleInternational journal of cancer2025

The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer.

Layla Andour, Sophie C Hagenaars, Kiki Vangangelt, Janneke Aalberts, Valerie Rebattu, Dorien M A Berends van der Meer, Elma Meershoek-Klein Kranenbarg, Katja N Gaarenstroom, Christi J van Asperen, Rob A E M Tollenaar and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Layla AndourDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-0073-9601
Sophie C HagenaarsDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-9121-1975
Kiki VangangeltDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Janneke AalbertsDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Valerie RebattuDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Dorien M A Berends van der MeerDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Elma Meershoek-Klein KranenbargDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Katja N GaarenstroomDepartment of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, The Netherlands.
Christi J van AsperenDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Rob A E M TollenaarDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Wilma E MeskerDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
TESTBREAST study team

Funding

BollenstreekfondsBontius StichtingFonds NutsOhraGenootschap Landgoed KeukenhofPink RibbonStichting A Sister's HopeStichting ZabawasTandengoudTeam Westland
6 · The paper itself

Abstract

Women with an inherited pathogenic variant (PV) in a breast cancer (BC) susceptibility gene, or familial predisposition (FP) have an increased risk to develop BC. There is a need for improvement of screening methods due to interval cancers and radiation exposure. The aim of the TESTBREAST study is to develop a blood test suitable for early diagnosis. Here, the clinical composition of participants is provided. From 2010 to 2022, 1108 women were included in the TESTBREAST study, with currently 750 participants suitable for serum analysis. The median follow-up was 7 years [1-14]. Of the 1108 participants, 70% (n = 728) had a PV. BC was diagnosed in 16.5% (n = 124), mainly stage I-II (68.5%), and mostly BRCA1 (n = 47, 47%) and BRCA2 (n = 29, 29%) carriers. Invasive cancer was diagnosed in 100 cases: 76% (n = 76) had a PV with a median age of 49 [26-68] at diagnosis, whereas 24% (n = 24) had a FP, with a median age of 51 years [25-65]. The general population (the Netherlands) is aged 61 years on average at diagnosis. Triple negative breast cancer (TNBC) occurred in 51% (n = 39) of the TESTBREAST women with a PV, whereas this was 11% in the general population. Within the TESTBREAST cohort, BRCA carriers were younger at diagnosis and often had the aggressive TNBC subtype. Improvement of current screening methods for early detection is especially important for this group of high-risk women to reduce interval cancers, exposure to radiation, and to improve survival.

Indexed as

Breast NeoplasmsEarly Detection of CancerAdultAgedBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansMiddle AgedBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanbreast cancergermline mutationhereditary breast and ovarian cancerhigh‐riskscreening

Identifiers

PMID40232159
PMCPMC12178100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.